JP2017531038A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017531038A5 JP2017531038A5 JP2017538466A JP2017538466A JP2017531038A5 JP 2017531038 A5 JP2017531038 A5 JP 2017531038A5 JP 2017538466 A JP2017538466 A JP 2017538466A JP 2017538466 A JP2017538466 A JP 2017538466A JP 2017531038 A5 JP2017531038 A5 JP 2017531038A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- salt
- pharmaceutical composition
- configuration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 12
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- WZFOPYGRZNUWSP-UHFFFAOYSA-N 7-oxa-2-azaspiro[3.5]nonane Chemical compound C1NCC11CCOCC1 WZFOPYGRZNUWSP-UHFFFAOYSA-N 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- CMVJYZNBMRJICR-UHFFFAOYSA-N 2-fluoro-6-methylaniline Chemical compound CC1=CC=CC(F)=C1N CMVJYZNBMRJICR-UHFFFAOYSA-N 0.000 claims description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 239000012736 aqueous medium Substances 0.000 claims description 2
- -1 carboxylate ester Chemical class 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 230000006806 disease prevention Effects 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 229960000329 ribavirin Drugs 0.000 claims description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 2
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 229940121649 protein inhibitor Drugs 0.000 claims 1
- 239000012268 protein inhibitor Substances 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- GFWAQJYBSDXTOR-UHFFFAOYSA-N Cc1cccc(F)c1NC(c1cc(CCN(C(c(cc2)ccc2N)=O)c2c-3cccc2)c-3[s]1)=O Chemical compound Cc1cccc(F)c1NC(c1cc(CCN(C(c(cc2)ccc2N)=O)c2c-3cccc2)c-3[s]1)=O GFWAQJYBSDXTOR-UHFFFAOYSA-N 0.000 description 1
- 229940076851 F protein inhibitor Drugs 0.000 description 1
- 229940122277 RNA polymerase inhibitor Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14188494 | 2014-10-10 | ||
| EP14188494.0 | 2014-10-10 | ||
| PCT/GB2015/052944 WO2016055791A1 (en) | 2014-10-10 | 2015-10-08 | Novel 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017531038A JP2017531038A (ja) | 2017-10-19 |
| JP2017531038A5 true JP2017531038A5 (2) | 2018-11-22 |
| JP6675407B2 JP6675407B2 (ja) | 2020-04-01 |
Family
ID=51842340
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017538467A Withdrawn JP2017531039A (ja) | 2014-10-10 | 2015-10-08 | 新規５，６−ジヒドロ−４Ｈ−ベンゾ［ｂ］チエノ−［２，３−ｄ］アゼピン誘導体 |
| JP2017538466A Active JP6675407B2 (ja) | 2014-10-10 | 2015-10-08 | 新規５，６−ジヒドロ−４Ｈ−ベンゾ［ｂ］チエノ−［２，３−ｄ］アゼピン誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017538467A Withdrawn JP2017531039A (ja) | 2014-10-10 | 2015-10-08 | 新規５，６−ジヒドロ−４Ｈ−ベンゾ［ｂ］チエノ−［２，３−ｄ］アゼピン誘導体 |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US10189863B2 (2) |
| EP (2) | EP3204389B1 (2) |
| JP (2) | JP2017531039A (2) |
| KR (1) | KR20170058921A (2) |
| CN (1) | CN106852144B (2) |
| AU (1) | AU2015329789B2 (2) |
| BR (1) | BR112017005104B1 (2) |
| CA (1) | CA2957868C (2) |
| EA (1) | EA201790796A8 (2) |
| IL (1) | IL250823A0 (2) |
| MX (1) | MX2017004652A (2) |
| SG (1) | SG11201701184WA (2) |
| WO (2) | WO2016055792A1 (2) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017005104B1 (pt) | 2014-10-10 | 2022-08-23 | Pulmocide Limited | Derivados de 5,6-di-hidro-4h-benzotieno-[2,3-d]azepina, seus usos, composição farmacêutica e processo para a preparação dos mesmos |
| JP6694886B2 (ja) | 2014-12-18 | 2020-05-20 | プルモシデ リミテド | ４，５−ジヒドロ−６Ｈ−チエノ［３，２−ｄ］ベンゾアゼピン誘導体及び呼吸器合胞体ウイルス（ＲＳＶ）感染を治療するためのその使用 |
| MY197231A (en) | 2015-07-22 | 2023-06-06 | Enanta Pharm Inc | Benzodiazepine derivatives as rsv inhibitors |
| CN108699077B (zh) | 2016-01-15 | 2021-03-02 | 英安塔制药有限公司 | 作为rsv抑制剂的杂环化合物 |
| BR112018014958A2 (pt) | 2016-02-03 | 2019-01-08 | Janssen Sciences Ireland Uc | produtos de combinação para o tratamento de rsv |
| US10626126B2 (en) * | 2016-04-08 | 2020-04-21 | Pulmocide Limited | Compounds |
| US10398706B2 (en) | 2017-01-06 | 2019-09-03 | Enanta Pharmaceuticals, Inc. | Heteroaryldiazepine derivatives as RSV inhibitors |
| AU2018221820B2 (en) | 2017-02-16 | 2023-11-02 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of benzodiazepine derivatives |
| US10752598B2 (en) | 2017-06-07 | 2020-08-25 | Enanta Pharmaceuticals, Inc. | Aryldiazepine derivatives as RSV inhibitors |
| WO2019006291A1 (en) * | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
| WO2019006295A1 (en) * | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
| CA3077309A1 (en) | 2017-09-29 | 2019-04-04 | Enanta Pharmaceuticals, Inc. | Combination pharmaceutical agents as rsv inhibitors |
| NZ764647A (en) | 2017-11-13 | 2025-12-19 | Enanta Pharm Inc | Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives |
| US10647711B2 (en) | 2017-11-13 | 2020-05-12 | Enanta Pharmaceuticals, Inc. | Azepin-2-one derivatives as RSV inhibitors |
| US10975094B2 (en) | 2018-04-11 | 2021-04-13 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| KR102926658B1 (ko) | 2019-03-18 | 2026-02-11 | 이난타 파마슈티칼스, 인코포레이티드 | Rsv 억제제로서의 벤조디아제핀 유도체 |
| WO2020210246A1 (en) * | 2019-04-09 | 2020-10-15 | Enanta Pharmaceuticals, Inc, | Heterocyclic compounds as rsv inhibitors |
| AU2020357452B2 (en) | 2019-10-04 | 2026-01-29 | Enanta Pharmaceuticals, Inc | Antiviral heterocyclic compounds |
| US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| UY39032A (es) | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | Compuestos heterocíclicos como agentes antivirales |
| US11534439B2 (en) | 2020-07-07 | 2022-12-27 | Enanta Pharmaceuticals, Inc. | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors |
| US11945824B2 (en) | 2020-10-19 | 2024-04-02 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
| IL305189A (en) | 2021-02-26 | 2023-10-01 | Enanta Pharm Inc | Heterocyclic antiviral compounds |
| AR129003A1 (es) | 2022-04-07 | 2024-07-03 | Enanta Pharm Inc | Compuestos heterocíclicos antivirales |
| US12162857B2 (en) | 2022-04-27 | 2024-12-10 | Enanta Pharmaceuticals, Inc. | Antiviral compounds |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5693635A (en) | 1993-07-29 | 1997-12-02 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| EP1177176B1 (en) | 1999-04-28 | 2006-04-19 | Aventis Pharma Deutschland GmbH | Tri-aryl acid derivatives as ppar receptor ligands |
| EP2240029A4 (en) * | 2008-01-07 | 2012-08-22 | Synta Pharmaceuticals Corp | COMPOUNDS FOR USE AGAINST INFLAMMATORY AND IMMUNOMIC DISEASES |
| WO2011005842A1 (en) | 2009-07-09 | 2011-01-13 | Gilead Sciences, Inc. | Anti-rsv compounds |
| JP5819305B2 (ja) | 2009-10-13 | 2015-11-24 | リガンド・ファーマシューティカルズ・インコーポレイテッド | 造血成長因子模倣小分子化合物およびそれらの使用 |
| BR112013002112B1 (pt) | 2010-07-29 | 2021-04-06 | Rigel Pharmaceuticals, Inc. | Composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável, ou de uma composição |
| WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| SG11201700851WA (en) | 2014-08-05 | 2017-03-30 | Alios Biopharma Inc | Combination therapy for treating a paramyxovirus |
| BR112017005104B1 (pt) * | 2014-10-10 | 2022-08-23 | Pulmocide Limited | Derivados de 5,6-di-hidro-4h-benzotieno-[2,3-d]azepina, seus usos, composição farmacêutica e processo para a preparação dos mesmos |
| CN108699077B (zh) | 2016-01-15 | 2021-03-02 | 英安塔制药有限公司 | 作为rsv抑制剂的杂环化合物 |
| BR112018014958A2 (pt) | 2016-02-03 | 2019-01-08 | Janssen Sciences Ireland Uc | produtos de combinação para o tratamento de rsv |
| WO2019006291A1 (en) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
| WO2019006295A1 (en) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
-
2015
- 2015-10-08 BR BR112017005104-4A patent/BR112017005104B1/pt active IP Right Grant
- 2015-10-08 CN CN201580054496.3A patent/CN106852144B/zh active Active
- 2015-10-08 AU AU2015329789A patent/AU2015329789B2/en active Active
- 2015-10-08 CA CA2957868A patent/CA2957868C/en active Active
- 2015-10-08 EP EP15784440.8A patent/EP3204389B1/en active Active
- 2015-10-08 JP JP2017538467A patent/JP2017531039A/ja not_active Withdrawn
- 2015-10-08 MX MX2017004652A patent/MX2017004652A/es unknown
- 2015-10-08 EA EA201790796A patent/EA201790796A8/ru unknown
- 2015-10-08 US US15/516,809 patent/US10189863B2/en active Active
- 2015-10-08 JP JP2017538466A patent/JP6675407B2/ja active Active
- 2015-10-08 EP EP15782045.7A patent/EP3204388B1/en active Active
- 2015-10-08 US US15/305,003 patent/US9732098B2/en active Active
- 2015-10-08 WO PCT/GB2015/052945 patent/WO2016055792A1/en not_active Ceased
- 2015-10-08 KR KR1020177006394A patent/KR20170058921A/ko not_active Withdrawn
- 2015-10-08 SG SG11201701184WA patent/SG11201701184WA/en unknown
- 2015-10-08 WO PCT/GB2015/052944 patent/WO2016055791A1/en not_active Ceased
-
2017
- 2017-02-27 IL IL250823A patent/IL250823A0/en active IP Right Grant
- 2017-07-06 US US15/642,637 patent/US9926335B2/en active Active
-
2018
- 2018-02-22 US US15/902,077 patent/US10035810B2/en active Active
- 2018-07-12 US US16/033,464 patent/US10273249B2/en active Active
-
2019
- 2019-03-11 US US16/298,460 patent/US10472375B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017531038A5 (2) | ||
| JP2017537949A5 (2) | ||
| JP2009535352A5 (2) | ||
| JP2018021051A5 (2) | ||
| JP2020507589A5 (2) | ||
| JP2016530259A5 (2) | ||
| CY1119880T1 (el) | Παραγωγα πυρρολοπυριμιδινης για χρηση στη θεραπεια ιικων λοιμωξεων | |
| JP2016525102A5 (2) | ||
| JP2013518107A5 (2) | ||
| JP2017523225A5 (2) | ||
| JP2011528713A5 (2) | ||
| JP2013534248A5 (2) | ||
| JP2013508279A5 (2) | ||
| JP2020097577A5 (2) | ||
| SI2932970T1 (en) | Antiviral therapy | |
| JP2017523169A5 (2) | ||
| JP2014526554A5 (2) | ||
| JP2007501809A5 (2) | ||
| JP2019526596A5 (2) | ||
| JP2015521156A5 (2) | ||
| JP2017517565A5 (2) | ||
| JP2019505529A5 (2) | ||
| JP2018527301A5 (ja) | アジリジン含有ｄｎａアルキル化剤 | |
| JP2011513410A5 (2) | ||
| JP2019527724A5 (2) |